vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）与Walker & Dunlop, Inc.（WD）财务数据对比。点击上方公司名可切换其他公司
INTEGRA LIFESCIENCES HOLDINGS CORP的季度营收约是Walker & Dunlop, Inc.的1.3倍（$434.9M vs $340.0M），Walker & Dunlop, Inc.同比增速更快（-0.4% vs -1.7%），INTEGRA LIFESCIENCES HOLDINGS CORP自由现金流更多（$-5.4M vs $-680.1M），过去两年Walker & Dunlop, Inc.的营收复合增速更高（22.1% vs 8.6%）
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
Walker & Dunlop, Inc.是美国乃至全球规模领先的商业地产金融与咨询服务机构，为客户提供覆盖商业地产领域的多元金融解决方案及专业咨询服务，业务辐射全球多个市场，在行业内拥有深厚的资源积累与广泛的市场认可度。
IART vs WD — 直观对比
营收规模更大
IART
是对方的1.3倍
$340.0M
营收增速更快
WD
高出1.3%
-1.7%
自由现金流更多
IART
多$674.7M
$-680.1M
两年增速更快
WD
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $434.9M | $340.0M |
| 净利润 | — | $-13.9M |
| 毛利率 | 50.8% | — |
| 营业利润率 | 5.3% | -17.2% |
| 净利率 | — | -12.9% |
| 营收同比 | -1.7% | -0.4% |
| 净利润同比 | — | -131.0% |
| 每股收益（稀释后） | $-0.03 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IARTWD
| Q4 25 | $434.9M | $340.0M | ||
| Q3 25 | $402.1M | $337.7M | ||
| Q2 25 | $415.6M | $319.2M | ||
| Q1 25 | $382.7M | $237.4M | ||
| Q4 24 | $442.6M | $341.5M | ||
| Q3 24 | $380.8M | $292.3M | ||
| Q2 24 | $418.2M | $270.7M | ||
| Q1 24 | $368.9M | $228.1M |
净利润IARTWD
| Q4 25 | — | $-13.9M | ||
| Q3 25 | $-5.4M | $33.5M | ||
| Q2 25 | $-484.1M | $34.0M | ||
| Q1 25 | $-25.3M | $2.8M | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | $-10.7M | $28.8M | ||
| Q2 24 | $-12.4M | $22.7M | ||
| Q1 24 | $-3.3M | $11.9M |
毛利率IARTWD
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — | ||
| Q1 24 | 56.1% | — |
营业利润率IARTWD
| Q4 25 | 5.3% | -17.2% | ||
| Q3 25 | 2.9% | 13.6% | ||
| Q2 25 | -123.4% | 14.5% | ||
| Q1 25 | -4.0% | 2.2% | ||
| Q4 24 | 8.0% | 15.3% | ||
| Q3 24 | -2.1% | 12.8% | ||
| Q2 24 | -0.7% | 10.4% | ||
| Q1 24 | 1.1% | 6.0% |
净利率IARTWD
| Q4 25 | — | -12.9% | ||
| Q3 25 | -1.3% | 9.9% | ||
| Q2 25 | -116.5% | 10.6% | ||
| Q1 25 | -6.6% | 1.2% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | -2.8% | 9.9% | ||
| Q2 24 | -3.0% | 8.4% | ||
| Q1 24 | -0.9% | 5.2% |
每股收益（稀释后）IARTWD
| Q4 25 | $-0.03 | $-0.41 | ||
| Q3 25 | $-0.07 | $0.98 | ||
| Q2 25 | $-6.31 | $0.99 | ||
| Q1 25 | $-0.33 | $0.08 | ||
| Q4 24 | $0.25 | $1.32 | ||
| Q3 24 | $-0.14 | $0.85 | ||
| Q2 24 | $-0.16 | $0.67 | ||
| Q1 24 | $-0.04 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $263.7M | $299.3M |
| 总债务越低越好 | $726.6M | — |
| 股东权益账面价值 | $1.0B | $1.7B |
| 总资产 | $3.6B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资IARTWD
| Q4 25 | $263.7M | $299.3M | ||
| Q3 25 | $267.9M | $274.8M | ||
| Q2 25 | $253.6M | $233.7M | ||
| Q1 25 | $273.3M | $181.0M | ||
| Q4 24 | $273.6M | $279.3M | ||
| Q3 24 | $277.6M | $179.8M | ||
| Q2 24 | $296.9M | $208.1M | ||
| Q1 24 | $663.1M | $216.5M |
总债务IARTWD
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
股东权益IARTWD
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.5B | $1.7B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.7B |
总资产IARTWD
| Q4 25 | $3.6B | $5.1B | ||
| Q3 25 | $3.6B | $5.8B | ||
| Q2 25 | $3.7B | $4.7B | ||
| Q1 25 | $4.1B | $4.5B | ||
| Q4 24 | $4.0B | $4.4B | ||
| Q3 24 | $4.1B | $4.6B | ||
| Q2 24 | $4.1B | $4.2B | ||
| Q1 24 | $4.1B | $3.8B |
负债/权益比IARTWD
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $-664.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.4M | $-680.1M |
| 自由现金流率自由现金流/营收 | -1.2% | -200.0% |
| 资本支出强度资本支出/营收 | 4.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-31.1M | $-2.2B |
8季度趋势，按日历期对齐
经营现金流IARTWD
| Q4 25 | $11.8M | $-664.3M | ||
| Q3 25 | $40.9M | $-948.1M | ||
| Q2 25 | $8.9M | $-238.5M | ||
| Q1 25 | $-11.3M | $-281.1M | ||
| Q4 24 | $50.7M | $129.4M | ||
| Q3 24 | $22.5M | $-202.0M | ||
| Q2 24 | $40.4M | $-237.8M | ||
| Q1 24 | $15.8M | $38.4M |
自由现金流IARTWD
| Q4 25 | $-5.4M | $-680.1M | ||
| Q3 25 | $25.8M | $-950.4M | ||
| Q2 25 | $-11.2M | $-241.0M | ||
| Q1 25 | $-40.2M | $-284.7M | ||
| Q4 24 | $21.1M | $116.4M | ||
| Q3 24 | $-7.2M | $-204.0M | ||
| Q2 24 | $10.7M | $-241.7M | ||
| Q1 24 | $291.0K | $35.2M |
自由现金流率IARTWD
| Q4 25 | -1.2% | -200.0% | ||
| Q3 25 | 6.4% | -281.5% | ||
| Q2 25 | -2.7% | -75.5% | ||
| Q1 25 | -10.5% | -120.0% | ||
| Q4 24 | 4.8% | 34.1% | ||
| Q3 24 | -1.9% | -69.8% | ||
| Q2 24 | 2.6% | -89.3% | ||
| Q1 24 | 0.1% | 15.4% |
资本支出强度IARTWD
| Q4 25 | 4.0% | 4.6% | ||
| Q3 25 | 3.8% | 0.7% | ||
| Q2 25 | 4.8% | 0.8% | ||
| Q1 25 | 7.6% | 1.5% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.8% | 0.7% | ||
| Q2 24 | 7.1% | 1.4% | ||
| Q1 24 | 4.2% | 1.4% |
现金转化率IARTWD
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× | ||
| Q1 24 | — | 3.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
WD
暂无分部数据
